CA3013336A1 - Buffer formulations for enhanced antibody stability - Google Patents
Buffer formulations for enhanced antibody stability Download PDFInfo
- Publication number
- CA3013336A1 CA3013336A1 CA3013336A CA3013336A CA3013336A1 CA 3013336 A1 CA3013336 A1 CA 3013336A1 CA 3013336 A CA3013336 A CA 3013336A CA 3013336 A CA3013336 A CA 3013336A CA 3013336 A1 CA3013336 A1 CA 3013336A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody formulation
- formulation
- buffered
- antibody
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 295
- 238000009472 formulation Methods 0.000 title claims abstract description 283
- 239000000872 buffer Substances 0.000 title claims abstract description 152
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 93
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 59
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 57
- 239000000600 sorbitol Substances 0.000 claims abstract description 57
- 159000000021 acetate salts Chemical class 0.000 claims abstract description 53
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 50
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 50
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 50
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract description 50
- 239000004475 Arginine Substances 0.000 claims abstract description 37
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 37
- 150000002411 histidines Chemical class 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims description 79
- 150000001413 amino acids Chemical group 0.000 claims description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 claims description 21
- 235000017281 sodium acetate Nutrition 0.000 claims description 21
- 229940087562 sodium acetate trihydrate Drugs 0.000 claims description 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 19
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 17
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 15
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 15
- 208000011231 Crohn disease Diseases 0.000 claims description 15
- 201000004681 Psoriasis Diseases 0.000 claims description 15
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 14
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 11
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 150000001484 arginines Chemical class 0.000 claims 4
- 229960002964 adalimumab Drugs 0.000 abstract description 57
- 150000001483 arginine derivatives Chemical class 0.000 abstract description 28
- 230000002378 acidificating effect Effects 0.000 abstract description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 6
- 229960002885 histidine Drugs 0.000 description 73
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 42
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 42
- 229960003121 arginine Drugs 0.000 description 32
- 239000000178 monomer Substances 0.000 description 30
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 27
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 27
- 230000027455 binding Effects 0.000 description 27
- 230000001225 therapeutic effect Effects 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 235000002639 sodium chloride Nutrition 0.000 description 18
- 239000008351 acetate buffer Substances 0.000 description 17
- 230000002776 aggregation Effects 0.000 description 16
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 15
- 238000004220 aggregation Methods 0.000 description 13
- 238000002296 dynamic light scattering Methods 0.000 description 13
- 239000013628 high molecular weight specie Substances 0.000 description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 11
- 229930195725 Mannitol Natural products 0.000 description 11
- 229960000106 biosimilars Drugs 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000594 mannitol Substances 0.000 description 11
- 235000010355 mannitol Nutrition 0.000 description 11
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 10
- 238000005277 cation exchange chromatography Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 9
- 239000003381 stabilizer Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 6
- 230000006240 deamidation Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000006317 isomerization reaction Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000002736 nonionic surfactant Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 208000002557 hidradenitis Diseases 0.000 description 5
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000012510 peptide mapping method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000013456 study Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 4
- 239000012062 aqueous buffer Substances 0.000 description 4
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical class [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 4
- 238000005251 capillar electrophoresis Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 4
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical class [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical class [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical class [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000013022 formulation composition Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- OZBJWQQAAQSQPL-WCCKRBBISA-N acetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N OZBJWQQAAQSQPL-WCCKRBBISA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- -1 arginine salt Chemical class 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 239000012537 formulation buffer Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- SJHOBWUQRVIODN-RVZXSAGBSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 SJHOBWUQRVIODN-RVZXSAGBSA-N 0.000 description 1
- JDRBFCVPTDOJOL-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1.OC(=O)CC(O)(C(O)=O)CC(O)=O JDRBFCVPTDOJOL-JEDNCBNOSA-N 0.000 description 1
- SKYVLKLRMFUTLN-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)[C@@H](N)CC1=CN=CN1 SKYVLKLRMFUTLN-JEDNCBNOSA-N 0.000 description 1
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- CUXLIVVHHYUEEV-UHFFFAOYSA-L C(C)(=O)[O-].[Na+].[Na+].C(C)(=O)O.C(C)(=O)[O-] Chemical compound C(C)(=O)[O-].[Na+].[Na+].C(C)(=O)O.C(C)(=O)[O-] CUXLIVVHHYUEEV-UHFFFAOYSA-L 0.000 description 1
- BHKSYEZGBQDNRW-SCGRZTRASA-N C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O Chemical compound C(CCC(=O)O)(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O BHKSYEZGBQDNRW-SCGRZTRASA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960002223 arginine aspartate Drugs 0.000 description 1
- 229960004246 arginine glutamate Drugs 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000012494 forced degradation Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 238000005621 mannosylation reaction Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013458 shaking study Methods 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290654P | 2016-02-03 | 2016-02-03 | |
| US62/290,654 | 2016-02-03 | ||
| PCT/US2017/016040 WO2017136433A1 (en) | 2016-02-03 | 2017-02-01 | Buffer formulations for enhanced antibody stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3013336A1 true CA3013336A1 (en) | 2017-08-10 |
Family
ID=58046768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3013336A Pending CA3013336A1 (en) | 2016-02-03 | 2017-02-01 | Buffer formulations for enhanced antibody stability |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11285210B2 (OSRAM) |
| EP (1) | EP3411401A1 (OSRAM) |
| JP (1) | JP7084308B2 (OSRAM) |
| CN (1) | CN109563161A (OSRAM) |
| AU (1) | AU2017213775A1 (OSRAM) |
| CA (1) | CA3013336A1 (OSRAM) |
| MX (1) | MX2018009341A (OSRAM) |
| WO (1) | WO2017136433A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106170298B (zh) | 2013-10-16 | 2024-01-09 | 前瞻疗法公司 | 用于提高抗体稳定性的缓冲液制剂 |
| EP2946766B1 (en) * | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| MX2018009341A (es) | 2016-02-03 | 2019-05-15 | Oncobiologics Inc | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| WO2019246455A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| AU2020207124A1 (en) * | 2019-01-11 | 2021-07-29 | Samsung Bioepis Co., Ltd. | Pharmaceutical composition comprising antibody, device comprising same, and use thereof |
| JP2022548950A (ja) * | 2019-09-19 | 2022-11-22 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ｐｃｓｋ９抗体を利用したコレステロール関連疾患の予防または治療方法 |
| EP4146175A1 (en) | 2020-05-08 | 2023-03-15 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| WO2022135395A1 (zh) * | 2020-12-22 | 2022-06-30 | 百奥泰生物制药股份有限公司 | 稳定的抗体制剂及其制备方法和应用 |
| GB202115121D0 (en) * | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
| GB202115127D0 (en) * | 2021-10-21 | 2021-12-08 | Ucb Biopharma Sprl | Formulations |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1331892A (en) | 1991-02-01 | 1992-09-07 | Coulter Corporation | Method of producing f(ab')2 fragments of immunoglobulins |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| KR20010043323A (ko) | 1998-05-06 | 2001-05-25 | 제넨테크, 인크. | 이온 교환 크로마토그래피에 의한 단백질 정제 방법 |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| NZ555692A (en) | 2002-07-19 | 2009-02-28 | Abbott Biotech Ltd | Treatment of TNF alpha related disorders |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| US8227241B2 (en) | 2004-03-12 | 2012-07-24 | Unigene Laboratories, Inc. | Bacterial host cell for the direct expression of peptides |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| KR100996801B1 (ko) | 2005-03-08 | 2010-11-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 항-ＭＡｄＣＡＭ 항체 조성물 |
| JP5757495B2 (ja) | 2005-05-16 | 2015-07-29 | アッヴィ バイオテクノロジー リミテッド | びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用 |
| JP5442251B2 (ja) | 2005-05-26 | 2014-03-12 | サイトス バイオテクノロジー アーゲー | 拡張可能な発酵方法 |
| EP2390267B1 (en) | 2005-06-07 | 2013-06-05 | ESBATech - a Novartis Company LLC | Stable and soluble antibodies inhibiting TNF(alpha) |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AR058140A1 (es) | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| TWI424161B (zh) | 2005-11-01 | 2014-01-21 | Abbvie Biotechnology Ltd | 利用生物標記診斷關節黏連脊椎炎之方法及組合物 |
| WO2007117490A2 (en) | 2006-04-05 | 2007-10-18 | Abbott Biotechnology Ltd. | Antibody purification |
| EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
| CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| EP2708242A3 (en) | 2006-04-10 | 2014-03-26 | Abbott Biotechnology Ltd | Uses and compositions for treatment of ankylosing spondylitis |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| CN103316402A (zh) | 2006-06-30 | 2013-09-25 | 艾伯维生物技术有限公司 | 自动注射装置 |
| WO2008032712A1 (fr) | 2006-09-11 | 2008-03-20 | Immuno-Biological Laboratories Co., Ltd. | Anticorps monoclonal et son utilisation |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| EP2500414A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| CA2842964A1 (en) | 2006-09-13 | 2008-03-20 | Abbvie Inc. | Cell culture improvements |
| US8034906B2 (en) | 2006-10-27 | 2011-10-11 | Abbott Biotechnology Ltd. | Crystalline anti-hTNFalpha antibodies |
| EP2142560A4 (en) | 2007-03-30 | 2010-12-01 | Abbott Lab | RECOMBINANT EXPRESSION VECTOR ELEMENTS (REVE) FOR INCREASING THE EXPRESSION OF RECOMBINANT PROTEINS IN HOST CELLS |
| CN105567627B (zh) | 2007-04-26 | 2020-09-29 | 中外制药株式会社 | 使用含高浓度氨基酸的培养基的细胞培养方法 |
| WO2008150491A2 (en) | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
| EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| CA2697163A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| EP2205280B1 (en) | 2007-09-27 | 2019-09-04 | Amgen Inc. | Pharmaceutical formulations |
| KR20150080038A (ko) | 2007-11-30 | 2015-07-08 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| WO2009073805A2 (en) * | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
| KR20100120289A (ko) | 2008-01-15 | 2010-11-15 | 애보트 게엠베하 운트 콤파니 카게 | 분말상 단백질 조성물 및 이의 제조 방법 |
| EP2240581B1 (en) | 2008-01-15 | 2016-05-11 | AbbVie Inc. | Improved mammalian expression vectors and uses thereof |
| EP2081025B1 (en) | 2008-01-15 | 2010-03-10 | Universiteit Utrecht Holding B.V. | Method for determining the amino acid sequence of peptides |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| JP2011517672A (ja) | 2008-03-24 | 2011-06-16 | アボツト・バイオテクノロジー・リミテツド | 骨損失を治療するための方法及び組成物 |
| PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
| NZ592095A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography |
| AU2009307737B2 (en) | 2008-10-20 | 2015-07-23 | Abbvie Inc. | Viral inactivation during purification of antibodies |
| WO2010048190A2 (en) | 2008-10-20 | 2010-04-29 | Abbott Laboratories | Antibodies that bind to il-12 and methods of purifying the same |
| CA2738243C (en) | 2008-10-29 | 2020-09-29 | Wyeth Llc | Formulations of single domain antigen binding molecules |
| JP2012510468A (ja) | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
| US20120053080A1 (en) | 2009-03-09 | 2012-03-01 | Juan Cui | Protein markers identification for gastric cancer diagnosis |
| CA2760185A1 (en) | 2009-05-04 | 2010-11-11 | Abbott Biotechnology Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha antibodies |
| CN102459603B (zh) | 2009-06-02 | 2013-11-06 | 瑞泽恩制药公司 | 岩藻糖基化缺陷型细胞 |
| CA2763164A1 (en) | 2009-06-05 | 2010-12-09 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| US20110059079A1 (en) | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody Coformulations |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| BR112012030530A2 (pt) | 2010-05-18 | 2022-12-20 | Abbvie Inc | Aparelho e processo para purificação de proteínas |
| CA2799915C (en) | 2010-05-25 | 2023-09-26 | Genentech, Inc. | Methods of purifying polypeptides |
| LT2575884T (lt) | 2010-06-03 | 2018-09-25 | Abbvie Biotechnology Ltd | Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui |
| EP2618904A1 (en) | 2010-09-20 | 2013-07-31 | AbbVie Inc. | Purification of antibodies using simulated moving bed chromatography |
| US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| CA2813747A1 (en) | 2010-10-11 | 2012-04-19 | Chen Wang | Processes for purification of proteins |
| US8821865B2 (en) * | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| NZ611862A (en) | 2010-12-28 | 2015-05-29 | Chugai Pharmaceutical Co Ltd | Animal cell culturing method |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
| JP5897708B2 (ja) | 2011-07-01 | 2016-03-30 | アムジエン・インコーポレーテツド | 哺乳類細胞培養物 |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| AU2012318590B2 (en) | 2011-10-04 | 2017-05-18 | Expression Pathology, Inc. | SRM/MRM assay for the ephrin type-A receptor 2 protein |
| HK1200464A1 (en) | 2011-10-24 | 2015-08-07 | Abbvie Inc. | Immunobinders directed against tnf |
| US20140288278A1 (en) | 2011-10-31 | 2014-09-25 | Joseph Nti-Gyabaah | Chromatography process for resolving heterogeneous antibody aggregates |
| WO2013114165A1 (en) | 2012-01-30 | 2013-08-08 | Dr Reddy's Laboratories Limited | Process of obtaining glycoprotein composition with increased afucosylation content |
| WO2013114164A1 (en) | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Method for obtaining glycoprotein composition with increased afucosylation content |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US20150150982A1 (en) | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| PE20191815A1 (es) | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| JP5874587B2 (ja) | 2012-09-10 | 2016-03-02 | 株式会社島津製作所 | アミノ酸配列解析方法及び装置 |
| NO2760138T3 (OSRAM) | 2012-10-01 | 2018-08-04 | ||
| EP2906683B1 (en) | 2012-10-15 | 2017-05-31 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| EP2934587A4 (en) | 2012-12-18 | 2016-08-03 | Merck Sharp & Dohme | Liquid formulations for an anti-TNF-alpha-antibody |
| JP6533932B2 (ja) | 2012-12-28 | 2019-06-26 | アボット カーディオバスキュラー システムズ インコーポレイテッド | 抗体を含む治療用組成物 |
| HK1207960A1 (en) | 2013-03-12 | 2016-02-19 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014158231A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| WO2014151901A1 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Improvement of mammalian cell culture performance through surfactant supplementation of feed media |
| JP6465794B2 (ja) | 2013-04-25 | 2019-02-06 | 株式会社カネカ | Ｆａｂ型抗体の分泌量を増大できるＦｄ鎖遺伝子又はＬ鎖遺伝子 |
| WO2014182658A1 (en) | 2013-05-06 | 2014-11-13 | Abbvie Inc. | Compositions for cell culture and methods of using the same |
| AR096713A1 (es) | 2013-06-25 | 2016-01-27 | Cadila Healthcare Ltd | Proceso de purificación para anticuerpos monoclonales |
| US20160266141A1 (en) | 2013-10-03 | 2016-09-15 | Bioanalytix, Inc. | Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic |
| CN106170298B (zh) | 2013-10-16 | 2024-01-09 | 前瞻疗法公司 | 用于提高抗体稳定性的缓冲液制剂 |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015140700A1 (en) | 2014-03-19 | 2015-09-24 | Dr. Reddy's Laboratories Limited | Cell culture process |
| EP3050557A1 (en) * | 2014-05-23 | 2016-08-03 | Ares Trading S.A. | Liquid pharmaceutical composition |
| HUP1400510A1 (hu) | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| CN105044222B (zh) | 2014-12-19 | 2017-09-12 | 浙江辉肽生命健康科技有限公司 | 生物活性多肽的分析测试和鉴定方法 |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| AR103544A1 (es) * | 2015-01-28 | 2017-05-17 | Mabxience S A | FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a |
| CN105779394B (zh) | 2015-03-20 | 2020-03-24 | 广东东阳光药业有限公司 | 一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法 |
| CA3010598A1 (en) | 2016-01-06 | 2017-07-13 | Oncobiologics, Inc. | Modulation of afucosylated species in a monoclonal antibody composition |
| CA3010600A1 (en) | 2016-01-06 | 2017-07-13 | Oncobiologics, Inc. | Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition |
| MX2018009341A (es) | 2016-02-03 | 2019-05-15 | Oncobiologics Inc | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
| MX2018009339A (es) | 2016-02-04 | 2019-01-10 | Oncobiologics Inc | Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas. |
-
2017
- 2017-02-01 MX MX2018009341A patent/MX2018009341A/es unknown
- 2017-02-01 US US16/072,991 patent/US11285210B2/en active Active
- 2017-02-01 CN CN201780019727.6A patent/CN109563161A/zh active Pending
- 2017-02-01 WO PCT/US2017/016040 patent/WO2017136433A1/en not_active Ceased
- 2017-02-01 AU AU2017213775A patent/AU2017213775A1/en not_active Abandoned
- 2017-02-01 EP EP17705527.4A patent/EP3411401A1/en not_active Withdrawn
- 2017-02-01 JP JP2018540113A patent/JP7084308B2/ja active Active
- 2017-02-01 CA CA3013336A patent/CA3013336A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019504086A (ja) | 2019-02-14 |
| WO2017136433A1 (en) | 2017-08-10 |
| JP7084308B2 (ja) | 2022-06-14 |
| AU2017213775A1 (en) | 2018-08-16 |
| US11285210B2 (en) | 2022-03-29 |
| US20190030163A1 (en) | 2019-01-31 |
| EP3411401A1 (en) | 2018-12-12 |
| CN109563161A (zh) | 2019-04-02 |
| MX2018009341A (es) | 2019-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11285210B2 (en) | Buffer formulations for enhanced antibody stability | |
| US10772960B2 (en) | Stable aqueous formulations of adalimumab | |
| AU2014337263B2 (en) | Buffer formulations for enhanced antibody stability | |
| CN103998060B (zh) | 使用糖与多元醇的结合物稳定的依那西普制剂 | |
| CN107635581A (zh) | 用于单克隆抗体的稳定液体制剂 | |
| AU2016382786A1 (en) | Buffered formulations of bevacizumab | |
| HUE029849T2 (en) | Liquid pharmaceutical composition | |
| TWI787161B (zh) | 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物 | |
| HUE035707T2 (en) | Pharmaceutical composition containing a biological drug | |
| JP2022547162A (ja) | 抗ＩＬ－２３ｐ１９抗体製剤 | |
| TWI771335B (zh) | 穩定藥學調配物 | |
| HK1230934B (zh) | 用於提高抗体稳定性的缓冲液制剂 | |
| HK1230934A1 (en) | Buffer formulations for enhanced antibody stability | |
| HK1204921B (en) | Stable liquid formulation of etanercept | |
| HK1204921A1 (en) | Stable liquid formulation of etanercept | |
| HK1200720B (en) | Etanercept formulations stabilized with combinations of sugars and polyols |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220128 |
|
| EEER | Examination request |
Effective date: 20220128 |
|
| EEER | Examination request |
Effective date: 20220128 |
|
| EEER | Examination request |
Effective date: 20220128 |